8-K: Eyenovia Amends Loan Agreement, Modifies Lender Stock Conversion Rights and Ownership Limits

Eyenovia, Inc. has entered into a Third Amendment to its Loan and Security Agreement, adjusting the terms for lenders to convert up to $10.0 million of outstanding principal into common stock, including beneficial ownership limitations and provisions for fundamental transactions.

Summary

• Eyenovia, Inc. (the "Company") signed a Third Amendment to its Loan and Security Agreement on May 30, 2025, with Avenue Capital Management II, L.P. and its affiliated lenders (the "Lenders").
• The original Loan and Security Agreement, dated November 22, 2022, provided for term loans up to an aggregate principal amount of $15.0 million.
• A Second Amendment, dated February 21, 2025, granted the Lenders an option to convert up to $10.0 million of the principal amount into shares of the Company's common stock at a price of $1.68 per share (the "Conversion Option").
• The Third Amendment introduces a beneficial ownership limitation, preventing a Lender from exercising the Conversion Option if, after conversion, they (together with affiliates) would beneficially own more than 9.99% of the Company's outstanding common stock.
• Lenders have the flexibility to increase or decrease this beneficial ownership limitation up to 19.99% by providing prior written notice to the Company, with any increase becoming effective 61 days after such notice.
• The amendment also stipulates that in the event of a "fundamental transaction" (e.g., merger, sale of substantially all assets, change of control, reclassification), a Lender will be entitled to receive the same kind and amount of securities, cash, or other consideration they would have received had they exercised the Conversion Option immediately prior to such transaction, without regard to the beneficial ownership limitation.
• The paragraph containing the beneficial ownership limitation cannot be amended unless the Company's stockholders approve a resolution to eliminate this prohibition.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the potential for dilution exists, the amendment clarifies and formalizes terms of an existing financing arrangement, which can be seen as a positive for financial stability and lender relations. The beneficial ownership limits offer some protection, and the fundamental transaction clause protects the lenders' rights, which is standard for such agreements.

Positives

• The amendment clarifies the terms of the existing loan and conversion option, providing certainty for both the Company and its Lenders.
• The beneficial ownership limitation (initially 9.99%) provides some protection against immediate, large-scale dilution from a single lender's conversion.
• The fundamental transaction clause ensures the Lenders' conversion rights are protected in the event of a change of control or other significant corporate events, which can be beneficial for securing financing terms.

Negatives

• The potential for future dilution exists if Lenders exercise the Conversion Option, as up to $10.0 million of debt can be converted into common stock at $1.68 per share.
• The ability for Lenders to increase their beneficial ownership limit up to 19.99% could lead to a significant concentration of ownership and potential influence over corporate governance.
• The conversion price of $1.68 per share may be below the Company's future market price, potentially leading to dilution for existing shareholders upon conversion.

Risks

• **Share Dilution Risk**: The exercise of the Conversion Option by Lenders will increase the number of outstanding shares of common stock, which could dilute the ownership percentage of existing shareholders and potentially depress the per-share value.
• **Control and Influence Risk**: If Lenders convert a significant portion of their debt into equity, especially up to the 19.99% beneficial ownership limit, they could gain substantial influence over the Company's corporate governance and strategic decisions.
• **Fundamental Transaction Impact**: While protecting Lenders, the provision allowing conversion without beneficial ownership limits during a fundamental transaction could result in a larger, more immediate equity issuance than otherwise permitted, potentially impacting the terms or outcome of such a transaction.

Future Outlook

The document primarily details an amendment to an existing financing agreement and does not provide explicit forward-looking statements regarding the Company's operational or financial performance. It outlines the future mechanics of debt-to-equity conversion and beneficial ownership limits for the Lenders.

Management Comments

• Michael Rowe, Chief Executive Officer, signed the Form 8-K on behalf of Eyenovia, Inc., indicating formal acknowledgment and approval of the Third Amendment.

Industry Context

This amendment is a routine corporate finance activity for a publicly traded biotechnology company like Eyenovia, which often relies on debt and equity financing to fund research, development, and commercialization efforts. The terms of such agreements, particularly those involving convertible debt, are critical for managing capital structure and potential dilution, common considerations in the capital-intensive biotech sector.

Comparison to Industry Standards

• The beneficial ownership limitation of 9.99% (with an option to increase to 19.99%) is a common protective clause in convertible debt agreements, designed to prevent a single investor from immediately gaining a controlling stake without further shareholder approval, aligning with typical governance practices in the biotech industry.
• The inclusion of a 'fundamental transaction' clause, which protects the conversion rights of lenders in the event of a merger or acquisition, is standard practice in venture debt and convertible security agreements across various industries, including biotech, ensuring lenders' economic interests are preserved during corporate changes.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for future dilution if Lenders exercise the Conversion Option, as more shares will be issued. The beneficial ownership limitation provides some protection against immediate, massive dilution from a single lender, but the ability for Lenders to increase this limit to 19.99% could still lead to significant ownership concentration.
• **Lenders (Avenue Capital Management II, L.P. and affiliates)**: Their rights to convert debt into equity are clarified and protected, especially in the event of a fundamental transaction, ensuring their investment interests are preserved. They gain flexibility to adjust their beneficial ownership limit within a defined range.
• **Company (Eyenovia, Inc.)**: The amendment formalizes and clarifies terms of an existing financing agreement, providing a clear framework for potential debt-to-equity conversion. It also imposes a restriction on amending the beneficial ownership limitation without stockholder approval, which could affect future financing flexibility.

Next Steps

• The Company will continue to operate under the terms of the amended Loan and Security Agreement.
• Lenders may, at their discretion, exercise the Conversion Option in the future, subject to the beneficial ownership limitations and other terms outlined in the Third Amendment.
• The Company will need to ensure compliance with the beneficial ownership limitation and the amendment prohibition clause regarding stockholder approval for any future changes to this specific limitation.

Key Dates

Recommendation

Keywords

Eyenovia, Loan and Security Agreement, Debt Conversion, Equity Dilution, Beneficial Ownership, SEC Filing, 8-K, Corporate Finance, Biotechnology, Ophthalmology